| Literature DB >> 28572816 |
Tatiana Rodrigues Alexandre1, Marta Lopes Lima1,2, Mariana Kolos Galuppo1, Juliana Tonini Mesquita1, Matilia Ana do Nascimento1, Augusto Leonardo Dos Santos3, Patricia Sartorelli3, Daniel Carvalho Pimenta4, Andre Gustavo Tempone1.
Abstract
BACKGROUND: Major drawbacks of the available treatment against Chagas disease (American trypanosomiasis) include its toxicity and therapeutic inefficiency in the chronic phase of the infection, which makes it a concern among neglected diseases. Therefore, the discovery of alternative drugs for treating chronic Chagas disease requires immediate action. In this work, we evaluated the mushroom Pleurotus salmoneostramineus in the search for potential antiparasitic compounds.Entities:
Keywords: Ergosterol; Mechanism of action; Pleurotus salmoneostramineus; Trypanosoma cruzi
Year: 2017 PMID: 28572816 PMCID: PMC5450401 DOI: 10.1186/s40409-017-0120-0
Source DB: PubMed Journal: J Venom Anim Toxins Incl Trop Dis ISSN: 1678-9180
Antitrypanosomal activity of ergosterol and cytotoxicity against mammalian cells
| Compound | IC50 (μg/mL) | IC50 (μg/mL) | CC50 (μg/mL) 95% CI | Selectivity index | Hemolytic activity (SD) |
|---|---|---|---|---|---|
| Ergosterol | 51.3 (46.0–57.0) | >100 | > 200 | > 3.9 | 7.03% (±11.6) |
| Benznidazole | 4.4 (3.7–5.1) | 1.9 (1.2–2.3) | > 200 | > 45.0 | nd |
IC50: 50% effective concentration; CC50: 50% cytotoxic concentration; 95% CI: 95% confidence interval; SI: selectivity index calculated as (SI = CC50 mammalian cell/IC50 trypomastigotes); nd: not determined
13C and 1H RMN data for ergosterol (75 MHz and 300 MHz)
| Position | δC EXP | δC LIT.a | δH EXP | δH LIT.b |
|---|---|---|---|---|
| 1 | 38.4 | 38.5 | ||
| 2 | 31.9 | 32.1 | ||
| 3 | 70.5 | 70.5 | 3.64 m (1H) | 3.61 m (1H) |
| 4 | 40.8 | 40.9 | ||
| 5 | 139.8 | 139.8 | ||
| 6 | 119.6 | 119.7 | 5.58 dd (5.5, 3.0 Hz, 1H) | 5.56 dd (5.4, 2.2 Hz, 1H) |
| 7 | 116.3 | 116.4 | 5.38 dd (5.4, 2.9 Hz, 1H) | 5.38 dd (5.4, 2.5 Hz, 1H) |
| 8 | 141.4 | 141.3 | ||
| 9 | 46.2 | 42.3 | ||
| 10 | 37.1 | 37.1 | ||
| 11 | 21.1 | 21.1 | ||
| 12 | 39.1 | 39.1 | ||
| 13 | 42.9 | 42.9 | ||
| 14 | 54.6 | 54.6 | ||
| 15 | 22.9 | 23.1 | ||
| 16 | 28.3 | 28.3 | ||
| 17 | 55.7 | 55.8 | ||
| 18 | 12.1 | 12.1 | 0.95 s (3H) | 0.95 s (3H) |
| 19 | 16.3 | 16.3 | 0.65 s (3H) | 0.63 s (3H) |
| 20 | 40.3 | 40.4 | ||
| 21 | 21.1 | 21.2 | 1.04 d (J = 6.6 Hz, 3H) | 1.00 d (J = 6.6 Hz, 3H) |
| 22 | 135.6 | 135.6 | 5.20 m (1H) | 5.20 m (1H) |
| 23 | 131.9 | 132.1 | 5.21 m (1H) | 5.20 m (1H) |
| 24 | 42.9 | 42.9 | ||
| 25 | 33.1 | 33.1 | ||
| 26 | 19.9 | 20.0 | 0.84 d (J = 6.7 Hz, 3H) | 0.84 d (J = 6.7 Hz, 3H) |
| 27 | 19.7 | 19.7 | 0.82 d (J = 6.7 Hz, 3H) | 0.83 d (J = 6.7 Hz, 3H) |
| 28 | 17.6 | 17.6 | 0.92 d (J = 6.6 Hz, 3H) | 0.95 d (3H) |
a [21]
b [22]
Fig. 1Structure of ergosterol confirmed by 13C, 1H RMN and GC-EI-MS
Fig. 2Effect of ergosterol on plasma membrane permeabilization of trypomastigotes of T. cruzi. Sytox Green (1 μM) fluorescence was measured spectrofluorimetrically every 20 min. Minimum and maximum permeabilization were obtained by non-treatment and Tx-100 0.5%, respectively. Fluorescence was quantified by calculating the mean percentages of untreated (0%) and Tx-100-treated (100%) trypomastigotes. *** p < 0.001 and **p < 0.002. A representative assay is shown
Fig. 3Effect of ergosterol in the mitochondrial function of trypomastigotes. Fluorescence of Mitotracker Red CM-H2XROS dye (500 nM) was spectrofluorimetrically measured after 60 min of incubation. Maximal and minimal fluorescence was achieved by non- or FCCP (10 μM) treatments, respectively. Fluorescence was quantified by calculating the mean percentage of untreated parasites (100%). *p < 0.001. A representative assay is shown
Fig. 4Effect of ergosterol in the ROS production of trypomastigotes. Fluorescence of H2DCF-DA was measured after 60 min of incubation. Fluorescence was quantified by calculating the mean percentage of untreated (0%) and sodium azide-treated (100%) trypomastigotes. ***(p < 0.001). A representative assay is shown